A systematic review and meta-analysis of randomized clinical trials has demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lower hemoglobin A1C, fasting glucose, body weight, and blood pressure in pediatric patients with obesity or type 2 diabetes. Covering 18 studies with 1,402 participants aged 6 to 17 years, the analysis revealed notable efficacy in glycemic control and weight loss, albeit with gastrointestinal adverse effects. Senior author Dr. Jingchuan Guo emphasized its contribution to clinical decision-making in this under-researched demographic.

Source: JAMA Pediatrics